Satralizumab is safe and effective for patients with myelin oligodendrocyte glycoprotein antibody-associated disease, the new phase 3 METEOROID trial shows.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/first-positive-phase-3-drug-trial-mogad-2026a1000d2s?src=rss
Author :
Publish date : 2026-04-24 12:12:00
Copyright for syndicated content belongs to the linked Source.
